Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

4679 - It’s Not Only About Weight Loss: Tackling Pancreatic Cancer-Associated Cachexia

Date

29 Sep 2019

Session

Poster Display session 2

Topics

Tumour Site

Pancreatic Adenocarcinoma

Presenters

Ana Leonor Matos

Citation

Annals of Oncology (2019) 30 (suppl_5): v253-v324. 10.1093/annonc/mdz247

Authors

A.L.V. Matos1, L. Fernandes1, H. Cunha2, J.A. Graca3, J. Barata4, M.T. Neves5, F.R. Alves5, J. Pereira1, F.A.S. Ferreira6, A. Freire Coelho7, M. Malheiro8, M.S. Mesquita Pinto1, M. Fontes e Sousa8, A. Placido1, A.M. Henriques Martins C. Mourão4

Author affiliations

  • 1 Medical Oncology, Centro Hospitalar de Lisboa Ocidental E.P.E. (CHLO)-Hospital São Francisco Xavier (HSFX), 1449-005 - Lisbon/PT
  • 2 Medical Oncology, Hospital Espirito Santo Évora, 7000 - Evora/PT
  • 3 Oncology Service, Centro Hospitalar de Lisboa Ocidental E.P.E. (CHLO)-Hospital São Francisco Xavier (HSFX), 1449-005 - Lisbon/PT
  • 4 Oncology Department, Centro Hospitalar de Lisboa Ocidental E.P.E. (CHLO)-Hospital São Francisco Xavier (HSFX), 1449-005 - Lisbon/PT
  • 5 Oncologia, Centro Hospitalar de Lisboa Ocidental E.P.E. (CHLO)-Hospital São Francisco Xavier (HSFX), 1449-005 - Lisbon/PT
  • 6 Medical Oncology Department, Centro Hospitalar de Lisboa Ocidental E.P.E. (CHLO)-Hospital São Francisco Xavier (HSFX), 1449-005 - Lisbon/PT
  • 7 Medical Oncology, Hospital de S. João, 4200–319 - Porto/PT
  • 8 Medical Oncology, Centro Hospitalar de Lisboa Ocidental(CHLO)-Hospital São Francisco Xavier (HSFX), 1449-005 - Lisbon/PT

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4679

Background

Cachexia affects 70-80% patients with pancreatic adenocarcinoma (PA). Systemic inflammation is a key feature of this multifactorial syndrome of unintended weight loss (WL). Despite being often described, cancer-associated cachexia (CAC) remains poorly understood and rarely recognized in clinical settings, therefore an unmet need. This study aims to acknowledge the effect of CAC in PA patients and to study the impact of WL, body mass index (BMI) and other available biomarkers (BM) on survival.

Methods

Retrospective analysis of PA patients treated in our institution between 2013 - 2018. Patients were categorized at baseline as having CAC if 1 of 2 criteria were met: WL > 5% from previous stable weight; BMI < 20 kg/ m2 and ongoing WL > 2%. Serum hemoglobin, c-reactive protein (CRP), albumin, inflammation-based score (Glasgow Prognostic Score mGPS), neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR) and cancer specific antigen CA 19-9 were assessed at baseline and at 3-month. Data analysis with descriptive statistics, t-test, chi-square test, cox regression and log-rank test were performed with StataIC.

Results

95 eligible patients (median age 72 [46;98], 60% female) were reviewed. At baseline, cachectic patients (CP) (74%), when compared to non-CP, had higher CA 19-9 (p = 0,047), more advanced disease (p = 0,001) lower BMI (p = 0,016), worse performance status (p = 0,016) and mean WL of 13,8 ± 6,7 (%) (p = 0,001). Also, NLR>3,5 (p = 0,001), PLR>150 (p = 0,018) and hypoalbuminemia (p = 0,004) were all statistically associated to CP. Median overall survival (OS) of non-CP was 19,13 months versus 5,03 months in CP (HR 2,69 95% CI 1,58-4,59, p = 0,001). In the latter, at baseline, higher CA 19.9 (HR 1,0 95% CI 1,01-1,021, p = 0,015), higher CRP (HR 1,21 95% CI 1,06-1,39, p = 0,006) and PLR>150 (HR 2,45; 95% CI 1,09-5,54, p = 0,031) were independent predictors of worst OS. In non-CP, normal baseline albumin (HR 0,04 95 CI 0,02-0,72, p = 0,029) was an independent predictor of better OS.

Conclusions

A better understanding of CAC in PA might improve outcomes for PA patients. Our study suggests that a prompt identification of prognostic BM may lead to a better standardized management of CAC and that nutritional parameters can be optimized, with impact on prognosis.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.